<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2389">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05503511</url>
  </required_header>
  <id_info>
    <org_study_id>NPT 2042 CL-101</org_study_id>
    <nct_id>NCT05503511</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects</brief_title>
  <official_title>A Single-center, Randomized, Placebo Controlled, Double-blind, Ascending Single-dose and Repeated-dose Trial to Determine the Safety and Pharmacokinetic Profile of NPT 2042 Soft-Gelatin Capsules Administered Orally to Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroPro Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroPro Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and&#xD;
      pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult&#xD;
      male and female subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-term goal of this program is to develop NPT 2042 an adjunct antiseizure treatment&#xD;
      for patients with medically intractable epilepsy. Prior to evaluating efficacy in the&#xD;
      intended patient population, safety and pharmacokinetics of NPT 2042 will be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2022</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 11 days</time_frame>
    <description>Absolute values and change from baseline after a single dose or after 7 days of repeated dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal lab test results</measure>
    <time_frame>Up to 11 days</time_frame>
    <description>Absolute values and change from baseline after a single dose or after 7 days of repeated dosing in clinical chemistry, hematology, and urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal vital signs</measure>
    <time_frame>Up to 11 days</time_frame>
    <description>Absolute values and change from baseline after a single dose or after 7 days of repeated dosing in vital signs (oral body temperature, respiratory rate, blood pressure, and heart rate).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal ECG</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Absolute values and change from baseline after a single dose or after 7 days of ECG intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Cmax</measure>
    <time_frame>0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose</time_frame>
    <description>Maximum (peak) observed concentration of NPT 2042.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Tmax</measure>
    <time_frame>0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose</time_frame>
    <description>Time to maximum observed concentrations of NPT 2042.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic half-life (t1/2)</measure>
    <time_frame>0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose</time_frame>
    <description>Time to terminal elimination half-life concentrations of NPT 2042.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic AUClast</measure>
    <time_frame>0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose</time_frame>
    <description>Area under the concentration-time curve from zero to the last concentration quantifiable for NPT 2042.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic AUCinf</measure>
    <time_frame>0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose</time_frame>
    <description>Area under the plasma concentration-time curve from time zero extrapolated to infinity for NPT 2042.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic CL/F</measure>
    <time_frame>0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose</time_frame>
    <description>Apparent total plasma clearance after oral administration of NPT 2042.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic VzF</measure>
    <time_frame>0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose</time_frame>
    <description>Apparent volume of distribution during terminal elimination phase after oral administration of NPT 2042.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose proportionality</measure>
    <time_frame>0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose</time_frame>
    <description>Dose proportionality of NPT 2042 will be assessed using the power model.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Epilepsy</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Epilepsy Intractable</condition>
  <arm_group>
    <arm_group_label>Part A; Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QD dosing of 10mg (1 day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A; Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QD dosing of 50mg (1 day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A; Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QD dosing of 160mg (1 day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B; Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 12-hour dosing of 20mg (7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B; Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 12-hour dosing of 40mg (7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B; Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 12-hour dosing of 80mg (7 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPT 2042 (bumetanide analog) or Matching Placebo</intervention_name>
    <description>Soft gelatin capsules</description>
    <arm_group_label>Part A; Cohort 1</arm_group_label>
    <arm_group_label>Part A; Cohort 2</arm_group_label>
    <arm_group_label>Part A; Cohort 3</arm_group_label>
    <arm_group_label>Part B; Cohort 1</arm_group_label>
    <arm_group_label>Part B; Cohort 2</arm_group_label>
    <arm_group_label>Part B; Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body mass index (BMI) of 18 to 32 kg/m2, inclusive&#xD;
&#xD;
          2. A minimum body weight of 50 kg for males and 45 kg for females&#xD;
&#xD;
          3. All females must have a negative serum pregnancy test at Screening and a negative&#xD;
             serum pregnancy test upon admission to the clinical research center.&#xD;
&#xD;
          4. Females must be of nonchild-bearing potential defined as permanently sterile (i.e.,&#xD;
             due to hysterectomy) or postmenopausal (defined as more than one year since last&#xD;
             menstrual period).&#xD;
&#xD;
          5. Male subjects with female partners of reproductive potential must agree to practice&#xD;
             abstinence or to use a condom (male subjects) plus an additional barrier method&#xD;
             (female partner) of contraception for the duration of the study and for at least 90&#xD;
             days after dosing; subjects must also agree to refrain from sperm donation for at&#xD;
             least 90 days after their last dose of IP.&#xD;
&#xD;
          6. Able to swallow capsules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of active or recurring clinically-significant cardiovascular, pulmonary,&#xD;
             renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic,&#xD;
             gastrointestinal, or metabolic disease requiring medical treatment.&#xD;
&#xD;
          2. Presence of an active malignancy or a malignancy of any type within the past five&#xD;
             years, other than squamous cell or basal cell carcinoma of the skin.&#xD;
&#xD;
          3. Personal or family history of long QT syndrome.&#xD;
&#xD;
          4. History or evidence of adverse symptoms associated with phlebotomy or blood donation&#xD;
             (e.g., prolonged bleeding after injury or shaving, frequent epistaxis or gingival&#xD;
             bleeding, bruises easily).&#xD;
&#xD;
          5. History of clinically significant vertigo, dizziness or orthostatic hypotension or any&#xD;
             vasovagal syncope or recurrent presyncope in connection with orthostatic challenge.&#xD;
&#xD;
          6. Reported use of or inability to refrain from or anticipated use of during the study&#xD;
&#xD;
               -  any prescription drug within 14 days prior to dosing;&#xD;
&#xD;
               -  any nonprescription drug, nutritional supplement, or vitamin within 7 days prior&#xD;
                  to dosing; NOTE: acetaminophen is allowed at a dose of ≤2000 mg/day&#xD;
&#xD;
               -  any known enzyme-inducer or enzyme-inhibitor including St. John's Wort within 28&#xD;
                  days prior to dosing, or&#xD;
&#xD;
               -  reported chronic exposure to enzyme inducers such as paint solvents or pesticides&#xD;
                  within 30 days of dosing.&#xD;
&#xD;
          7. Supine blood pressure (BP) less than 80/50 mmHg or greater than 140/90 mmHg.&#xD;
&#xD;
          8. Supine heart rate &lt;40 bpm and &gt;90 bpm.&#xD;
&#xD;
          9. History of drug abuse or current use of drugs of abuse or excessive ethanol intake&#xD;
&#xD;
         10. Current Smoking, vaping, hookah, chewing tobacco, or history of smoking/vaping/chewing&#xD;
             any substance&#xD;
&#xD;
         11. Average consumption of ≥3 caffeine-containing beverages or xanthine-containing foods&#xD;
             per day.&#xD;
&#xD;
         12. Positive urine drug, alcohol, or cotinine result at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daryl Hochman</last_name>
    <phone>(919) 812-0485</phone>
    <email>daryl@npt.io</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Cornelius</last_name>
      <phone>402-437-4926</phone>
      <phone_ext>4926</phone_ext>
      <email>jacob.cornelius@celerion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>July 28, 2022</study_first_submitted>
  <study_first_submitted_qc>August 12, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2022</study_first_posted>
  <last_update_submitted>October 21, 2022</last_update_submitted>
  <last_update_submitted_qc>October 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CNS Disorder</keyword>
  <keyword>Seizure Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bumetanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

